PTCT: Global rare disease growth driven by SUFIANCE, new assets, and disciplined financial strategy
Management highlighted strong financial positioning, global expansion of SUFIANCE, and a robust rare disease pipeline. Key growth drivers include international launches, new gene therapy assets, and disciplined operational strategy, with profitability and cash flow breakeven targeted this year.Base…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.